Navidea Biopharmaceuticals, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB; OTC: NAVBQ) develops and commercializes precision immunodiagnostic agents and immunotherapeutics targeting activated macrophages via its proprietary Manocept platform, which leverages the CD206 mannose receptor for applications in single photon emission computed tomography, positron emission tomography, gamma-scanning, intra-operative detection, optical-fluorescence imaging, and therapeutic delivery; core products and candidates include Lymphoseek (technetium Tc 99m tilmanocept injection) for lymphatic mapping in cancer surgery, Tc99m tilmanocept formulations for rheumatoid arthritis imaging, cardiovascular disease, Kaposi’s sarcoma, tuberculosis, and other macrophage-mediated inflammatory, autoimmune, infectious, and oncologic conditions, alongside historical neuroinflammation agents such as NAV4694. The company operates in the biotechnology sector with diagnostic substances and therapeutic development segments, serving physicians, clinicians, and patients in precision medicine markets focused on enhanced diagnostic accuracy, clinical decision-making, and targeted treatments primarily in North America. Founded in 1983 and headquartered in Dublin, Ohio, Navidea pursues global partnering and commercialization strategies; recent developments encompass a 2023 sale of its Cardinal Milestone Payment for $8 million and a $2.75 million equity line of credit to fund Phase IIb (NAV3-32) and Phase III (NAV3-33) trials, an extension of reverse stock split authority to July 2027 approved in 2025, and a voluntary Chapter 11 Subchapter V bankruptcy filing on October 1, 2025, to facilitate orderly restructuring while maintaining limited operations.
Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock
NYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)
Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel
Navidea Biopharmaceuticals, Inc. Presses Ahead, Embraces Opportunities
Why Is Navidea Biopharmaceutical (NAVB) Stock Down 13% Today?
Navidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American Determination
NYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)
Navidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial Officer
Navidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps Down
Navidea Biopharmaceuticals rejects ProPhase Labs offer
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
Navidea Biopharmaceuticals, Inc. Announces Distribution of Series K Preferred Stock to Holders of its Common Stock
Navidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash from Cardinal Health in Lieu of Contingent Milestone Payment